[Transport to an infected site of azithromycin by phagocyte cells].
Azithromycin is a new macrolide antibiotic developed by Pfizer. This compound has a 15 ring structure formed by adding a methyl-nitrogen to the 14-member lactone ring of erythromycin. Azithromycin has acid stability and significant improved activity against gram negative bacteria compared to other macrolides. Further, sustained high tissue levels of azithromycin have been demonstrated clinically and in basic research. There has been particular interest in the phagocyte delivery system of azithromycin to the site of infection. The mechanism is characterized by the intake of azithromycin by phagocytic cells which release the antibiotic at the site of infection. This report describes the mechanism of sustained high tissue levels by summarizing the data of Japanese and western clinical trials and research.
Enogaki
K
K
Central Research, Pfizer Pharmacenticals Inc.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D017963:Azithromycin / Q000378:metabolism / Q000493:pharmacokinetics*; D001692:Biological Transport; D004195:Disease Models, Animal; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D051379:Mice; D010586:Phagocytes / Q000378:metabolism*; D051381:Rats; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D017963:Azithromycin